Keybank National Association OH Trims Holdings in ChemoCentryx, Inc. (CCXI)

Keybank National Association OH reduced its stake in ChemoCentryx, Inc. (NASDAQ:CCXI) by 26.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 40,438 shares of the biopharmaceutical company’s stock after selling 14,544 shares during the period. Keybank National Association OH owned approximately 0.08% of ChemoCentryx worth $300,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CCXI. TIAA CREF Investment Management LLC increased its holdings in ChemoCentryx by 37.5% in the 1st quarter. TIAA CREF Investment Management LLC now owns 128,546 shares of the biopharmaceutical company’s stock valued at $936,000 after acquiring an additional 35,049 shares during the last quarter. Vanguard Group Inc. increased its holdings in ChemoCentryx by 4.1% in the 1st quarter. Vanguard Group Inc. now owns 1,198,730 shares of the biopharmaceutical company’s stock valued at $8,727,000 after acquiring an additional 47,475 shares during the last quarter. Geode Capital Management LLC increased its holdings in ChemoCentryx by 4.6% in the 1st quarter. Geode Capital Management LLC now owns 196,708 shares of the biopharmaceutical company’s stock valued at $1,432,000 after acquiring an additional 8,697 shares during the last quarter. Renaissance Technologies LLC increased its holdings in ChemoCentryx by 31.0% in the 1st quarter. Renaissance Technologies LLC now owns 616,581 shares of the biopharmaceutical company’s stock valued at $4,489,000 after acquiring an additional 146,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in ChemoCentryx by 35.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 79,299 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 20,955 shares during the last quarter. Institutional investors own 49.15% of the company’s stock.

A number of analysts have issued reports on CCXI shares. Cowen and Company reiterated a “hold” rating on shares of ChemoCentryx in a report on Tuesday, August 8th. BidaskClub cut shares of ChemoCentryx from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 10th. Zacks Investment Research cut shares of ChemoCentryx from a “buy” rating to a “sell” rating in a research note on Friday, August 11th. Finally, ValuEngine cut shares of ChemoCentryx from a “hold” rating to a “sell” rating in a research note on Saturday, October 21st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. ChemoCentryx has an average rating of “Hold” and a consensus price target of $8.25.

COPYRIGHT VIOLATION WARNING: This piece was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://ledgergazette.com/2017/11/19/keybank-national-association-oh-trims-holdings-in-chemocentryx-inc-ccxi.html.

ChemoCentryx, Inc. (CCXI) opened at $7.32 on Friday. ChemoCentryx, Inc. has a 52 week low of $6.13 and a 52 week high of $10.80.

ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. sell-side analysts anticipate that ChemoCentryx, Inc. will post -0.67 earnings per share for the current fiscal year.

ChemoCentryx Profile

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply